Targeted Treatment: The Role of Injectables in Weight Loss Management
Tracking # 20-1302677
Course overview
Injectable anti-obesity medications (AOMs) offer a novel approach to obesity management by targeting neurohormonal pathways to achieve sustained weight loss and improve metabolic health. Agents like liraglutide, semaglutide, and tirzepatide have demonstrated significant efficacy in clinical trials, with benefits including cardiometabolic risk reduction and treatment of sleep apnea. Incorporating AOMs into a comprehensive treatment plan that includes dietary, physical, and behavioral interventions is essential for optimizing outcomes. This educational activity will explore the mechanisms, efficacy, and safety profiles of injectable AOMs, emphasizing their integration into a comprehensive obesity treatment framework. This course will also discuss the role of interprofessional collaboration in delivering patient-centered obesity care for patients utilizing these medications.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Michigan Board of Pharmacy
Pharmacist
Disclosure statements
The following individuals were involved in developing this activity: L. Austin Fredrickson, MD, FACP, Liz Fredrickson, PharmD, BCPS, Susan Bowlin, DNP, FNP-BC, ACNP-BC, CBN, and Pamela Sardo, PharmD, BS. Austin Frederickson, Liz Frederickson, and Pamela Sardo have no conflict of interest or financial relationship or commercial or financial support relevant to this activity to report or disclose in the development of this activity. Susan Bowlin is a member of the Speaker’s Bureau for Eli Lilly and Novo Nordisk. Any potential conflicts of interest were mitigated.